Abstract
In 1796, Edward Jenner introduced the concept of vaccination with cowpox virus, an Orthopoxvirus within the family Poxviridae that elicits cross protective immunity against related orthopoxviruses, including smallpox virus (variola virus). Over time, vaccinia virus (VACV) replaced cowpox virus as the smallpox vaccine, and vaccination efforts eventually led to the successful global eradication of smallpox in 1979. VACV has many characteristics that make it an excellent vaccine and that were crucial for the successful eradication of smallpox, including (1) its exceptional thermal stability (a very important but uncommon characteristic in live vaccines), (2) its ability to elicit strong humoral and cell-mediated immune responses, (3) the fact that it is easy to propagate, and (4) that it is not oncogenic, given that VACV replication occurs exclusively within the host cell cytoplasm and there is no evidence that the viral genome integrates into the host genome. Since the eradication of smallpox, VACV has experienced a renaissance of interest as a viral vector for the development of recombinant vaccines, immunotherapies, and oncolytic therapies, as well as the development of next-generation smallpox vaccines. This revival is mainly due to the successful use and extensive characterization of VACV as a vaccine during the smallpox eradication campaign, along with the ability to genetically manipulate its large dsDNA genome while retaining infectivity and immunogenicity, its wide mammalian host range, and its natural tropism for tumor cells that allows its use as an oncolytic vector. This review provides an overview of new uses of VACV that are currently being explored for the development of vaccines, immunotherapeutics, and oncolytic virotherapies.
Keywords: cancer immunotherapy, oncolytic cancer therapy, smallpox, vaccines, vaccinia virus, viral vectors
Next-Generation Smallpox Vaccines
Smallpox was successfully eradicated through the efforts of the World Health Organization (WHO) in 1979.1,2 However, in the last decade there has been a renewed interest in the development of next-generation smallpox vaccines due to the threat of bioterrorism and the possible emergence of other orthopoxviruses (such as monkeypox virus) as significant human pathogens. Although the smallpox vaccines used during the smallpox eradication campaign (now called first-generation vaccines) were very efficacious, they were typically propagated in the skin of calves2 under conditions that did not adhere to good manufacturing practices (GMP). VACV strains widely used during the smallpox eradication campaign included the New York City Board of Health (NYCBH), Lister, and EM-63 (Table 1). These live vaccines were commonly administered by scarification with a bifurcated needle, leading to a cutaneous reaction due to local virus replication. The resulting scar at the site of inoculation, known as the “take,” has been historically accepted as the correlate of protection for smallpox.1-3 However, these first-generation smallpox vaccines were associated with a number of adverse reactions ranging from mild (e.g., malaise, mild rash, and fever) to severe (e.g., eczema vaccinatum, progressive vaccinia, and post-vaccinial encephalitis).2,4 Over the years, susceptibility to more severe complications was correlated with pre-existing conditions such as atopic dermatitis, immunosupression (e.g., due to HIV/AIDS and immunosuppressive therapy), and cardiac disease. Individuals with such conditions, or with contacts that have such conditions, are currently contraindicated for smallpox vaccination.5,6
Table 1. Some first and next-generation smallpox vaccines.
Vaccine (Parental Strain) |
Description |
Advantages |
Disadvantages |
Reference(s) |
---|---|---|---|---|
First Generation | ||||
Dryvax (NYCBH) |
Propagated in calf skin, used in the US eradication campaign, replaced by ACAM2000 in 2007 |
Well characterized, low pathogenicity, “take” (correlate of protection) |
Adverse reactions ranging from mild to severe |
2, 78 |
Lister |
Propagated mainly in calf skin, widely used in the eradication campaigns in UK, Africa, Asia, Oceania |
Well characterized, moderate pathogenicity, “take” (correlate of protection) |
Adverse reactions ranging from mild to severe |
2 |
EM-63 |
Propagated in calf skin, used in the former Soviet Union |
Well characterized, low pathogenicity, “take” (correlate of protection) |
Adverse reactions ranging from mild to severe |
2 |
Second Generation |
|
|
|
|
ACAM2000 (Dryvax) |
Single clone derived from Dryvax and propagated in Vero cells, FDA licensed and part of the US Strategic National Stockpile |
Improved manufacturing (produced under GMP), less neurovirulent, immunologically non-inferior to Dryvax in clinical trials, “take” (correlate of protection) |
Similar safety profile as Dryvax (adverse reactions ranging from mild to severe) |
9–12 |
Elstree-BN (Lister) |
Derived from the Lister/Elstree-RIVM strain and passaged in chicken embryo fibroblasts, Phase I clinical trials completed |
Improved manufacturing, “take” (correlate of protection) |
Adverse reactions ranging from mild to severe |
7, 54 |
CCSV (NYCBH) |
Cell-Culture Smallpox Vaccine (CCSV) propagated in MRC-5 cells, Phase I clinical trials completed |
Improved manufacturing, “take” (correlate of protection) |
Adverse reactions ranging from mild to severe |
8, 54 |
Third Generation |
|
|
|
|
Imvamune® (MVA) |
Derived from Modified Vaccinia Ankara (MVA) strain 571 and passaged in serum free chicken embryo fibroblasts, replication defective in most mammalian cells, under fast track status at the FDA (Phase III trials) |
Improved safety profile, extensive clinical testing |
Efficacy against smallpox unknown, boosting may be required for protection, no observable “take” |
13, 14, 16, 17, 54 |
NYVAC (Copenhagen) |
Derived from Copenhagen strain by deletion of 18 nonessential genes leading to a high degree of attenuation and reduced ability to grown in human cells |
Improved safety profile |
Efficacy against smallpox unknown, induces lower antibody responses in humans, boosting may be required for protection, no observable “take” |
18–20 |
LC16m8 (Lister) |
Derived from Lister strain by passage in rabbit kidney cells at low temperature and selection of small pock formation clone on chorioallantoic membranes, disruption in the B5R gene, licensed in Japan |
Improved safety profile (milder reactions in children and less virulent), “take” (correlate of protection) |
Efficacy against smallpox unknown |
21–26 |
Fourth Generation |
|
|
|
|
DNA Vaccines |
Single or combination of VACV IMV specific genes (A27, D8L, F9L, H3L, L1R), EEV specific genes (A33R, A56R, B5R), core antigens (A4L), or variola virus gene counterparts |
Improved safety profile, protection in animal models |
No clinical trials, boosting may be required for protection, no observable “take” |
27–30 |
Protein (Subunit) Vaccines |
Single or combination of VACV IMV specific genes (A27, H3L, L1R) and EEV specific genes (A33R, B5R) |
Improved safety profile, protection in animal models |
No clinical trials, boosting may be required for protection, no observable “take” |
31–33 |
T-cell Epitope Vaccines | Multi-T-cell epitope vaccine based on antigenic sequences and DNA-prime, peptide-boost | Improved safety profile, protection in mice | No clinical trials, boosting may be required for protection, no observable “take” | 34 |
A number of second-generation vaccines have been developed focusing on sterile cell culture techniques for vaccine propagation (Table 1). For example, the Elstree-BN vaccine developed by Bavarian Nordic was grown in chick embryo fibroblasts,7 and the cell-cultured smallpox vaccine (CCSV) developed by DynPort Vaccine Company was derived from the NYCBH strain grown on normal diploid MRC-5 human lung cell cultures.8 Similarly, Acambis (now part of Sanofi Pasteur) isolated a single clone derived from the Dryvax vaccine that was grown in Vero cells and named ACAM2000.9 ACAM2000 was less neurovirulent than Dryvax in mice and nonhuman primates,10 provided equivalent immunogenicity in clinical trials,11 and was licensed in 2007 in the US.12 However, the overall safety profile of ACAM2000 and other second-generation smallpox vaccines is still comparable to the first-generation vaccines such as Dryvax, with similar rates of complications.11
A number of highly attenuated strains of VACV have been developed and are now being considered as safer smallpox vaccine alternatives, called third-generation smallpox vaccines (Table 1). One example is modified vaccinia Ankara (MVA), that was developed by passage of VACV strain Ankara over 570 times in chick embryo fibroblasts.13 Inoculation with MVA leads to abortive infections in mammals and most mammalian cells, but expression of viral genes still occurs.14 This highly attenuated VACV strain has been extensively tested in humans and has sparked considerable interest because it has been demonstrated to be extremely safe.15 However, MVA propagation is limited to chick embryo fibroblasts and a few other mammalian cell lines where yield is low,14 and the immunogenicity is not as robust compared with previous smallpox vaccine generations. For example, immune responses in phase I and II clinical trials to an MVA-based vaccine developed by Bavarian Nordic (Imvamune®) are dose-dependent and can require two immunizations to achieve immune responses similar to first-generation vaccines.16,17
Genetic manipulation of the VACV genome has also played a role in the development of highly attenuated VACV strains. The Copenhagen strain of VACV was considered to have higher pathogenicity,2 but the deletion of 18 non-essential genes led to the highly attenuated NYVAC strain that is still immunogenic.18,19 However, NYVAC induces lower antibody responses in humans when compared with Dryvax or Lister first-generation vaccine strains, and it does not induce anti-A27 antibodies that are seen in the immune response to first-generation vaccines and can neutralize intracellular mature virus (IMV).20 Two major disadvantages of highly attenuated VACV strains such as MVA and NYVAC is that they do not produce a “take” in vaccinees and their efficacy against smallpox was never determined.
An additional third-generation vaccine is LC16m8, an attenuated VACV derived from the Lister strain that has an excellent safety profile.21-23 LC16m8 contains a mutation in the B5R gene, which causes the virus to produce smaller plaques and replicate less efficiently in Vero cells,24,25 but unlike MVA, LC16m8 produces a “take” in vaccinees.22,23 This vaccine was licensed in Japan and used in the 1970s eradication campaign, but since smallpox was no longer endemic at that time, its efficacy against smallpox is currently unknown. A disadvantage that must be considered is that LC16m8 does not induce neutralizing antibodies against the B5 protein, the main target for extracellular enveloped virus (EEV) neutralizing antibodies.26
A number of different approaches are being used for the development of the so-called fourth-generation smallpox vaccines that eliminate the possibility of the VACV vector to cause adverse events or revert to a more pathogenic phenotype (Table 1). These include the development of subunit and DNA vaccines typically composed of VACV (or variola virus counterpart) membrane proteins that elicit neutralizing antibodies against the IMV and EEV forms of the virus.27-33 A particularly new approach is the use of conserved and immunogenic multi-T-cell epitopes that are used in a DNA-prime, peptide boost vaccine regimen.34 These fourth-generation vaccines have shown to be protective using animal models, but none are currently being tested in clinical trials, and to be efficacious against smallpox they will likely require booster immunizations.
Vaccinia Viruses as Animal Vaccine Vectors
The successful use and extensive characterization of VACV during the smallpox eradication campaign, along with the ability to genetically manipulate its large dsDNA genome while retaining infectivity, its heat stability and low cost of production, makes VACV particularly attractive for the development of animal vaccines.35,36 A large number of antigens from animal pathogens have been expressed in VACV, and the majority elicit protective immune responses (examples shown in Table 2). The most successful recombinant VACV vaccine has been the oral vaccine for sylvatic rabies (Raboral V-RG®) that expresses the rabies glycoprotein (G).37,38 This recombinant virus is packaged into vaccine baits that are distributed in areas affected by rabies. The heat stability of the V-RG vaccine proved to be extremely helpful in sylvatic rabies vaccination programs, which have led to better control of rabies in Europe and North America.39 Several recombinant VACV vaccines engineered to express the fusion and hemagglutinin glycoproteins of rinderpest virus have also been developed,40,41 providing sterilizing immunity to cattle challenged with virulent rinderpest virus over one year after vaccination.41 Recombinant VACVs expressing heterologous viral antigens have also been protective against peste-des-petits-ruminants virus, vesicular stomatitis virus, Newcastle disease virus, canine distemper virus, and Rift Valley fever virus in a variety of animal species (reviewed in Table 2).
Table 2. Some vaccinia virus-vectored animal vaccines.
Pathogen (Species) | Parental VACV Strain | Protein(s) Expressed /Comments | Reference(s) |
---|---|---|---|
Rabies virus (foxes, raccoons, skunks, coyotes) |
Copenhagen |
Glycoprotein G, licensed in the US as Raboral V-RG® |
37–39 |
Rinderpest virus (ruminants, cattle, buffalo), Peste-des-petits-ruminants virus (goats and sheep) |
NYCBH, Copenhagen |
Rinderpest virus fusion (F) and hemagglutinin (H) genes |
40, 41, 79 |
Vesicular stomatitis virus (horses, cattle, pigs) |
Western Reserve (WR) |
Glycoprotein G |
80 |
Newcastle disease virus (chickens) |
Elstree |
Fusion (F) |
81, 82 |
Leishmania (dogs) |
MVA |
Tryparedoxin peroxidase (TRYP), DNA/MVA prime/boost |
83 |
Canine distemper virus (dogs) |
Copenhagen |
Measles virus fusion (F) or hemagglutinin (H) genes |
84 |
Echinococcus granulosus (marsupial wildlife, possums) |
Lister |
Eg95 (oncosphere-stage antigen) |
85 |
Rift Valley fever virus (cattle, sheep, zoonotic disease in humans) | Copenhagen | Glycoproteins Gn and Gc | 86 |
Vaccinia Viruses as Human Vaccine Vectors
The use of VACV as a vector for human vaccines against infections agents has also been extensively investigated (Table 3), with most of the effort focused on the development of vaccines against HIV. Initially, replication-competent VACVs were typically employed, but more recent efforts center on the use of replication-defective poxviruses due to safety concerns. In addition, replication-defective poxvirus vectors, including MVA, NYVAC, and avipoxviruses (such as canarypox virus and fowlpox virus), offer the advantage of allowing multiple booster immunizations even in subjects with pre-existing immunity.42 The only Phase III trial to show any evidence of protection against HIV has been the RV144 trial in Thailand.43 The RV144 vaccine regimen consisted of four priming injections of a recombinant canarypox expressing HIV-1 Gag, protease, and Env, followed by two booster immunizations with a recombinant Env subunit vaccine. The trial involved 16,402 subjects and the estimated vaccine efficacy (prevention of HIV-1 infection) was 31.2%.43 The results from the RV144 Thai trial, albeit modest, reinvigorated the HIV vaccine community and their interest in poxvirus-vectored HIV vaccines. A number of Phase I and II HIV clinical trials, usually in the form of a DNA prime and recombinant MVA or NYVAC boost, have shown that these vaccine regimens are safe, immunogenic, and have the potential to improve the efficacy obtained with the RV144 Thai trial (Table 3).
Table 3. Some vaccinia virus-vectored human vaccines.
Pathogen (Disease) | Vaccine Name (VACV Parental Strain) | Protein(s) Expressed | Comments | Reference(s) |
---|---|---|---|---|
HIV-1 (AIDS) |
Sanofi Pasteur ALVAC-HIV (canarypox) prime and VaxGen AIDSVAX subunit boost |
ALVAC-HIV: HIV-1 Gag and PR B; Env E AIDSVAX: HIV-1 Env B/E |
Used canarypox (an avian poxvirus), first phase III HIV vaccine clinical trial that yielded some protection (31.2% efficacy), revitalized the HIV vaccine community |
43 |
HIV-1 (AIDS) |
DNA prime and MVA-CMDR (MVA) boost |
DNA: HIV-1 Env A/B/C, Rev B, RT B, Gag A/B MVA-CMDR: HIV-1 Env E, Gag/Pol A |
Phase I/II trials completed, safe and immunogenic with T-cell and antibody responses |
87 |
HIV-1 (AIDS) |
DNA prime and NYVAC-C (Copenhagen) boost |
HIV-1 Gag, Pol, Nef, Env C |
Phase II trials completed, safe and immunogenic with T-cell and antibody responses (non-neutralizing) |
54, 88–90 |
HIV-1 (AIDS) |
MVA-B (MVA) |
HIV-1 Env, Gag, Pol, Nef B |
Phase I trial completed, safe, immunogenic with T-cell and antibody responses |
91 |
HIV-1 (AIDS) |
GeoVax pGA2/JS7 DNA and MVA/HIV62 (MVA) boost |
DNA (complex): HIV-1 Gag, PR, RT, Env, Tat, Rev, and Vpu MVA: HIV-1 Gag, PR, RT, and Env |
Produce non-infectious virus-like particles (VLPs), Phase I trial completed, Phase IIa ongoing, trial with inclusion of GM-CSF as an adjuvant started in 2012 |
54, 92 |
Plasmodium falciparum (Malaria) |
Chimpanzee Adenovirus (ChAd63) prime and MVA boost |
Merozoite surface protein 1 (MSP1), or T-cell multiple epitope fused to the thrombospondin-related adhesion protein (ME-TRAP), or apical membrane antigen 1 (AMA1) |
Three Phase I trials suggest that the chimpanzee adenovirus prime / MVA boost strategy is safe and highly immunogenic |
44–46 |
Mycobacterium tuberculosis (Tuberculosis) |
Aeras MVA85A (MVA) |
Highly conserved M. tuberculosis antigen 85A |
Aim is to boost immunity induced by the current tuberculosis vaccine M. bovis bacille Calmette-Guerin (BCG), Phase I trial completed and vaccine induced potent Th1 cell responses, Phase II trials ongoing |
47 |
Influenza virus (Influenza) |
MVA-NP+M1 (MVA) |
Influenza A Nucleoprotein (NP) and Matrix protein 1 (M1) |
Phase 1 trials concluded, safe and immunogenic (induces high T-cell responses) |
93 |
Hepatitis B virus (HBV) | DNA prime and MVA.HBs (MVA) boost | HBV S antigen (HBsAg) genotype D | Therapeutic vaccine trial resulted in variable immune responses that did not control HBV infection | 94 |
Recombinant MVA has also been extensively used alone or in prime-boost strategies in vaccine clinical trials for other viral diseases such as influenza and hepatitis B, as well as bacterial and parasitic diseases such as tuberculosis and malaria (Table 3). Three malaria Phase I trials with recombinant chimpanzee adenovirus (ChAd63) and MVA expressing different Plasmodium falciparum antigens have shown that this prime-boost strategy is safe and immunogenic.44-46 Likewise, Phase I trials with an MVA vector expressing the Mycobacterium tuberculosis 85A antigen, aimed to serve as a booster immunization after bacille Calmette-Guerin (BCG) vaccination, showed that the vaccine can induce potent Th1 responses.47 Lastly, a number of other constructs are being developed and investigated in pre-clinical trials, including vaccines against hepatitis C virus,48 respiratory syncytial virus,49 anthrax (with the advantage of being a dual vaccine against anthrax and smallpox),50 and Nipah virus.51
Vaccinia Viruses as Immunotherapeutic Cancer Vectors
The ability of VACV to induce potent immune responses to tumor-associated antigens (TAAs) expressed in its genome has been employed for the development of immunotherapies for cancer (Table 4). One example is PROSTVAC® (Bavarian Nordic), a therapeutic cancer vaccine for prostate cancer that consists of a replication-competent VACV prime followed by multiple replication-defective avian poxvirus (fowlpox) boosts.52,53 Both poxviruses express a modified prostate-specific antigen (PSA), along with three T-cell costimulatory molecules termed TRICOM (B7.1, ICAM-1, and LFA-3). The immune response to the altered PSA (with a single amino acid change in an HLA-A2 epitope) is aimed to target cancerous prostate cells, while the costimulatory molecules increase the immunogenicity of the constructs. This treatment has been studied in Phase II clinical trials in patients with metastatic castration-resistant prostate cancer, where treatment was well tolerated, death rate was reduced by 44%, and the median overall survival was 8.5 mo longer than in patients receiving control vectors.52,53 This increase in overall survival was noticeably superior to that afforded by the currently approved treatment (docetaxel, 2–3 mo increase in overall survival), and Phase III clinical trials are ongoing.52,54 Bavarian Nordic is also performing clinical trials with an MVA vector (MVA-BN® PRO) expressing two prostate TAAs, PSA along with prostatic acid phosphatase (PAP),54,55 and with MVA-BN® HER2, an MVA vector expressing the TAA human epidermal growth factor receptor 2 (HER2) to treat breast cancer.54,56
Table 4. Some vaccinia virus vectors used for cancer immunotherapy.
Cancer | Therapy Name (VACV Parental Strain) | Protein(s) Expressed | Comments | Reference(s) |
---|---|---|---|---|
Prostate |
Bavarian Nordic PROSTVAC-V (NYCBH) prime and PROSTVAC-F (fowlpox) boosters |
PSA and TRICOM (T-cell costimulatory molecules B7.1, ICAM-1, and LFA-3) |
Phase II trials showed an enhanced median overall survival in patients with metastatic castration-resistant prostate cancer, currently in Phase III trials |
52–54 |
Prostate |
Bavarian Nordic MVA-BN® PRO (MVA) |
PSA and PAP |
Under Phase I/II trials, additional studies targeting antigens to exosomes show improved efficacy |
54, 55 |
Various such as colorectal, renal, ovarian, fallopian peritoneal, prostate |
Oxford BioMedica TroVax® (MVA) |
Human oncofetal antigen 5T4 |
Alone or in conjunction with other treatments, 5T4 antibody responses correlated with increased survival, Phase II and III ongoing/completed |
54, 57–61 |
Breast |
Bavarian Nordic MVA-BN® HER2 (MVA-BN) |
Human epidermal growth factor receptor 2 (HER2) |
Phase I completed |
54, 56 |
Lung carcinoma, solid tumors |
Transgene TG4010 (MVA) |
Mucin-1 (MUC-1) and IL-2 |
Phase I completed, II/III ongoing |
54, 63, 64 |
Ovarian, melanoma |
VACV NY-ESO-1 (NYCBH) prime and fowlpox NY-ESO-1 boosters |
NY-ESO-1 (cancer/testis antigen) |
Phase II trials completed |
54, 62 |
Breast, lung, ovarian | Bavarian Nordic CV-301 (MVA-BN), formally known as PANVAC | Carcinoembryonic antigen (CEA), MUC-1, and TRICOM | Phase II trials ongoing | 54, 65 |
TroVax® (Oxford BioMedica) is an MVA vector that expresses the human oncofetal antigen 5T4, a placental glycoprotein overexpressed in a number of different cancers (Table 4).57 When administered alone or in conjuction with other treatments (e.g., chemotherapy and cytokines), Trovax® mounted high anti-5T4 immune responses that were associated with increased overall survival.54,57-61 Poxvirus vectors expressing another TAA, the cancer-testis NY-ESO-1 antigen, were tested in Phase II clinical trials in a VACV prime followed by fowlpox boost regimen with melanoma and ovarian cancer patients that were at risk for recurrence or progression after completion of their primary therapy.54,62 The trials provided evidence for an extended overall survival and progression-free survival in patients that developed detectable anti-NY-ESO-1 immune responses.62
TG4010 (Transgene SA) is an MVA vector that expresses mucin-1 (MUC-1), a TAA expressed by glandular epithelia and by some cancers, as well as the immostimulatory cytokine IL-2 (Table 4).63 Results from a Phase IIb study with non-small-cell lung cancer patients in combination with chemotherapy suggests that TG4010 has beneficial effects and additional trials are ongoing.54,64 Finally, CV-301 (Bavarian Nordic), formerly known as PANVAC, is an MVA vector that in addition to MUC-1, also expresses carcinoembryonic antigen (CEA) and the TRICOM set of T-cell costimulatory molecules, having a potential effect on multiple cancers.65 A recent pilot study in patients with metastatic breast and ovarian cancer suggests that CV-301 may be beneficial to patients and a Phase II study is underway.54,65
Vaccinia Viruses as Oncolytic Cancer Therapy Vectors
Oncolytic viruses are promising new therapies for the clinical treatment of cancers. As a replication-competent virus, VACV displays a natural tumor tropism and kills cancer cells through apoptosis and other mechanisms.66 Moreover, recombinant VACVs in which the vaccinia growth factor (VGF) and thymidine kinase (TK) genes have been deleted acquire enhanced tumor selectivity (tropism), likely because cancer cells overexpress epidermal growth factor receptor (EGFR) and have high metabolic rates that make TK expression by VACV dispensable.67,68 Systemic administration of these oncolytic VACV vectors (e.g., intravenously) targets both tumors and metastases, and current clinical trials show that VACV vectors can be an effective oncolytic cancer therapy (Table 5). In addition, recombinant VACVs expressing host immunomodulating genes such as human GM-CSF and other cytokines, anti-angiogenic agents, and extracellular matrix genes also show enhanced tumor selectivity and oncolytic effects.66 For example, JX-594 (Jennerex Biotherapeutics) is a TK negative VACV expressing GM-CSF. In patients with hepatocellular carcinoma, treatment with JX-594 resulted in antitumor and antivascular activities,69 and in clinical trials patients with metastatic liver cancer and metastatic melanoma tolerated treatment and anti-tumor effects were observed.70,71 Another example is vvDD-CDSR (Jennerex Biotherapeutics), a TK and VGF negative vector engineered to express a reporting gene (somatostatin receptor) for molecular in vivo imaging after systemic delivery, as well as the prodrug-activating enzyme cytosine deaminase for therapy with 5-fluorocytosine.72,73 These modifications allow vvDD-CDSR to be highly tumor selective and oncolytic. Finally, GL-ONC1 (Genelux), also known as GLV-1h68, is a light-emitting oncolytic VACV expressing a luciferase-green fluorescent protein (GFP) fusion gene and containing deletions in the F14.5L, TK, and A56R genes.74 In pre-clinical trials it showed tumor-specific replication and solid tumor size reduction.74-76 In addition, VACVs with tumor selectivity and light-emitting or imaging features (such as expression of somatostatin receptor and 111In-pentreteodide treatment) can be innovative and helpful tools to non-invasively detect and locate primary and metastatic tumors, as well as to track the therapeutic vector during treatment.72,77
Table 5. Some vaccinia virus vectors used for oncolytic cancer therapy.
Cancer | Therapy Name (VACV Parental Strain) | Protein(s) Expressed | Comments | Reference(s) |
---|---|---|---|---|
Various such as melanoma, colorectal, liver, lung, renal, squamous cell, head and neck |
Jennerex Biotherapeutics JX-594 (Dryvax, TK-) |
GM-CSF and β-galactosidase |
Antitumor and antivascular activities, Phase I and II trials ongoing/completed |
54, 69–71 |
Various such as melanoma, breast, liver, colorectal |
Jennerex vvDD-CDSR (Western Reserve, TK- and VGF-) |
Cytosine deaminase (CD) and somatostatin receptor (SMR) |
Highly selective and oncolytic for tumors with gene-directed enzyme prodrug therapy using 5-fluorocytosine, SMR gene is used for molecular imaging, Phase I trials ongoing |
54, 72, 73 |
Advanced solid tumors, head and neck, peritoneal | Genelux GL-ONC1 (Lister, F14.5L-, TK-, and A56R-) | Renilla luciferase-GFP fusion, β-galactosidase, β-glucuronidase | Tumor specific replication and solid tumor size reduction in pre-clinical trials, Phase I and II trials ongoing | 54, 74–76 |
Future Perspectives
Since the eradication of smallpox more than 30 y ago, VACV has experienced a renaissance of interest as a viral vector for the development of recombinant vaccines, immunotherapies, and oncolytic therapies, as well as the development of next-generation smallpox vaccines. This renewed interest in both replication-competent and replication-defective VACVs has driven a number of vaccine and therapeutic candidates to clinical trials. Replication-competent VACVs are used for oncolytic therapy, and as live vaccines they elicit superior immune responses, but safety is a concern due to potential adverse events. Conversely, replication-defective VACVs are not as immunogenic as their replication-competent counterparts, but are extremely safe and offer the capacity to be administered multiple times with minimal interference from pre-existing immunity. A number of approaches have been used to enhance the safety of replication-competent VACV vectors while maintaining their immunogenicity, such as the deletion of viral genes and expression of cytokines. A new approach under development to generate next-generation smallpox vaccines that are efficacious and safer is the addition of safety mechanisms to second-generation VACV vectors that should allow the conditional replication of the virus and the production of the “take,” the correlate of protection against smallpox (Hagen, Titong, and Verardi, unpublished data). With these built-in safety systems, VACV replication can be controlled so that adverse events in vaccinees and contacts can be treated with antibiotics. These new technologies can also be applied for the development of VACV vectors for human vaccines and therapies with enhanced safety features.
A range of potential new uses is under development in areas such as tumor imaging and enhanced oncolytic and tumor selectivity. The fact that VACV has the capacity to hold at least 25 kb of heterologous DNA while retaining infectivity also enables the development of multi-pathogen, multi-epitope polyvalent vaccines. Hence, it seems inevitable that this “old” vaccine will lead to “new” uses in the near and distant future.
Acknowledgments
The authors would like to thank Caitlin O’Connell for critical review of the manuscript. Work in our laboratory is currently supported by the US Department of Agriculture (USDA), the University of Connecticut Research Foundation (UCRF), and the University of Connecticut Office of Undergraduate Research (OUR).
Glossary
Abbreviations:
- VACV
vaccinia virus
- MVA
modified vaccinia Ankara
- IMV
intracellular mature virus
- EEV
extracellular enveloped virus
- TAA
tumor-associated antigen
- TK
thymidine kinase
- FDA
Food and Drug Administration
Footnotes
Previously published online: www.landesbioscience.com/journals/vaccines/article/21080
References
- 1.Wehrle PF. A reality in our time--certification of the global eradication of smallpox. J Infect Dis. 1980;142:636–8. doi: 10.1093/infdis/142.4.636. [DOI] [PubMed] [Google Scholar]
- 2.Fenner F, Henderson DA, Arita I, Jeek Z, Ladnyi ID. Smallpox and its eradication. Geneva, Switzerland: World Health Organization, 1988. [Google Scholar]
- 3.Moss B. Poxviridae: the viruses and their replication. In: Knipe DM, Howley PM, eds. Fields' virology. Philadelphia: Lippincott Williams & Wilkins, 2007:2906-45. [Google Scholar]
- 4.Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: results of ten statewide surveys. J Infect Dis. 1970;122:303–9. doi: 10.1093/infdis/122.4.303. [DOI] [PubMed] [Google Scholar]
- 5.Lane JM, Goldstein J. Evaluation of 21st-century risks of smallpox vaccination and policy options. Ann Intern Med. 2003;138:488–93. doi: 10.7326/0003-4819-138-6-200303180-00014. [DOI] [PubMed] [Google Scholar]
- 6.Kemper AR, Davis MM, Freed GL. Expected adverse events in a mass smallpox vaccination campaign. Eff Clin Pract. 2002;5:84–90. [PubMed] [Google Scholar]
- 7.Stittelaar KJ, van Amerongen G, Kondova I, Kuiken T, van Lavieren RF, Pistoor FH, et al. Modified vaccinia virus Ankara protects macaques against respiratory challenge with monkeypox virus. J Virol. 2005;79:7845–51. doi: 10.1128/JVI.79.12.7845-7851.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Greenberg RN, Kennedy JS, Clanton DJ, Plummer EA, Hague L, Cruz J, et al. Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial. Lancet. 2005;365:398–409. doi: 10.1016/S0140-6736(05)17827-1. [DOI] [PubMed] [Google Scholar]
- 9.Weltzin R, Liu J, Pugachev KV, Myers GA, Coughlin B, Blum PS, et al. Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat Med. 2003;9:1125–30. doi: 10.1038/nm916. [DOI] [PubMed] [Google Scholar]
- 10.Monath TP, Caldwell JR, Mundt W, Fusco J, Johnson CS, Buller M, et al. ACAM2000 clonal Vero cell culture vaccinia virus (New York City Board of Health strain)--a second-generation smallpox vaccine for biological defense. Int J Infect Dis. 2004;8(Suppl 2):S31–44. doi: 10.1016/j.ijid.2004.09.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.Frey SE, Newman FK, Kennedy JS, Ennis F, Abate G, Hoft DF, et al. Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. Vaccine. 2009;27:1637–44. doi: 10.1016/j.vaccine.2008.11.079. [DOI] [PubMed] [Google Scholar]
- 12.Greenberg RN, Kennedy JS. ACAM2000: a newly licensed cell culture-based live vaccinia smallpox vaccine. Expert Opin Investig Drugs. 2008;17:555–64. doi: 10.1517/13543784.17.4.555. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Mayr A, Stickl H, Müller HK, Danner K, Singer H. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author’s transl)] Zentralbl Bakteriol B. 1978;167:375–90. [PubMed] [Google Scholar]
- 14.Drexler I, Heller K, Wahren B, Erfle V, Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells. J Gen Virol. 1998;79:347–52. doi: 10.1099/0022-1317-79-2-347. [DOI] [PubMed] [Google Scholar]
- 15.Hochstein-Mintzel V, Hänichen T, Huber HC, Stickl H. [An attenuated strain of vaccinia virus (MVA). Successful intramuscular immunization against vaccinia and variola (author’s transl)] Zentralbl Bakteriol Orig A. 1975;230:283–97. [PubMed] [Google Scholar]
- 16.Vollmar J, Arndtz N, Eckl KM, Thomsen T, Petzold B, Mateo L, et al. Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine. 2006;24:2065–70. doi: 10.1016/j.vaccine.2005.11.022. [DOI] [PubMed] [Google Scholar]
- 17.von Krempelhuber A, Vollmar J, Pokorny R, Rapp P, Wulff N, Petzold B, et al. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine. 2010;28:1209–16. doi: 10.1016/j.vaccine.2009.11.030. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Tartaglia J, Perkus ME, Taylor J, Norton EK, Audonnet JC, Cox WI, et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology. 1992;188:217–32. doi: 10.1016/0042-6822(92)90752-B. [DOI] [PubMed] [Google Scholar]
- 19.Paoletti E, Tartaglia J, Taylor J. Safe and effective poxvirus vectors--NYVAC and ALVAC. Dev Biol Stand. 1994;82:65–9. [PubMed] [Google Scholar]
- 20.Midgley CM, Putz MM, Weber JN, Smith GL. Vaccinia virus strain NYVAC induces substantially lower and qualitatively different human antibody responses compared with strains Lister and Dryvax. J Gen Virol. 2008;89:2992–7. doi: 10.1099/vir.0.2008/004440-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Hashizume S, Yoshizawa H, Morita M, Suzuki K. Properties of attenuated mutant of vaccinia virus, LC16M8, derived from Lister strain. In: Quinnan GV, ed. Vaccinia viruses as vectors for vaccine antigens Proceedings of the Workshop on Vaccinia Viruses as Vectors for Vaccine Antigens. New York, N.Y.: Elsevier, 1985:87-99. [Google Scholar]
- 22.Saito T, Fujii T, Kanatani Y, Saijo M, Morikawa S, Yokote H, et al. Clinical and immunological response to attenuated tissue-cultured smallpox vaccine LC16m8. JAMA. 2009;301:1025–33. doi: 10.1001/jama.2009.289. [DOI] [PubMed] [Google Scholar]
- 23.Kennedy JS, Gurwith M, Dekker CL, Frey SE, Edwards KM, Kenner J, et al. Safety and immunogenicity of LC16m8, an attenuated smallpox vaccine in vaccinia-naive adults. J Infect Dis. 2011;204:1395–402. doi: 10.1093/infdis/jir527. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Takahashi-Nishimaki F, Funahashi S, Miki K, Hashizume S, Sugimoto M. Regulation of plaque size and host range by a vaccinia virus gene related to complement system proteins. Virology. 1991;181:158–64. doi: 10.1016/0042-6822(91)90480-Y. [DOI] [PubMed] [Google Scholar]
- 25.Kenner J, Cameron F, Empig C, Jobes DV, Gurwith M. LC16m8: an attenuated smallpox vaccine. Vaccine. 2006;24:7009–22. doi: 10.1016/j.vaccine.2006.03.087. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Johnson BF, Kanatani Y, Fujii T, Saito T, Yokote H, Smith GL. Serological responses in humans to the smallpox vaccine LC16m8. J Gen Virol. 2011;92:2405–10. doi: 10.1099/vir.0.034207-0. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Hooper JW, Custer DM, Thompson E. Four-gene-combination DNA vaccine protects mice against a lethal vaccinia virus challenge and elicits appropriate antibody responses in nonhuman primates. Virology. 2003;306:181–95. doi: 10.1016/S0042-6822(02)00038-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Sakhatskyy P, Wang S, Zhang C, Chou TH, Kishko M, Lu S. Immunogenicity and protection efficacy of subunit-based smallpox vaccines using variola major antigens. Virology. 2008;371:98–107. doi: 10.1016/j.virol.2007.09.029. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Pulford DJ, Gates A, Bridge SH, Robinson JH, Ulaeto D. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge. Vaccine. 2004;22:3358–66. doi: 10.1016/j.vaccine.2004.02.034. [DOI] [PubMed] [Google Scholar]
- 30.Hirao LA, Draghia-Akli R, Prigge JT, Yang M, Satishchandran A, Wu L, et al. Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J Infect Dis. 2011;203:95–102. doi: 10.1093/infdis/jiq017. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Fogg C, Lustig S, Whitbeck JC, Eisenberg RJ, Cohen GH, Moss B. Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol. 2004;78:10230–7. doi: 10.1128/JVI.78.19.10230-10237.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Davies DH, McCausland MM, Valdez C, Huynh D, Hernandez JE, Mu Y, et al. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J Virol. 2005;79:11724–33. doi: 10.1128/JVI.79.18.11724-11733.2005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Buchman GW, Cohen ME, Xiao Y, Richardson-Harman N, Silvera P, DeTolla LJ, et al. A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge. Vaccine. 2010;28:6627–36. doi: 10.1016/j.vaccine.2010.07.030. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Moise L, Buller RM, Schriewer J, Lee J, Frey SE, Weiner DB, et al. VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone. Vaccine. 2011;29:501–11. doi: 10.1016/j.vaccine.2010.10.064. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Moss B. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety. Proc Natl Acad Sci U S A. 1996;93:11341–8. doi: 10.1073/pnas.93.21.11341. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Yilma T. Applications of recombinant vaccinia virus for veterinary vaccines. Dev Biol Stand. 1994;82:201–9. [PubMed] [Google Scholar]
- 37.Wiktor TJ, Macfarlan RI, Reagan KJ, Dietzschold B, Curtis PJ, Wunner WH, et al. Protection from rabies by a vaccinia virus recombinant containing the rabies virus glycoprotein gene. Proc Natl Acad Sci U S A. 1984;81:7194–8. doi: 10.1073/pnas.81.22.7194. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Kieny MP, Lathe R, Drillien R, Spehner D, Skory S, Schmitt D, et al. Expression of rabies virus glycoprotein from a recombinant vaccinia virus. Nature. 1984;312:163–6. doi: 10.1038/312163a0. [DOI] [PubMed] [Google Scholar]
- 39.Pastoret PP, Brochier B. The development and use of a vaccinia-rabies recombinant oral vaccine for the control of wildlife rabies; a link between Jenner and Pasteur. Epidemiol Infect. 1996;116:235–40. doi: 10.1017/S0950268800052535. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Giavedoni L, Jones L, Mebus C, Yilma T. A vaccinia virus double recombinant expressing the F and H genes of rinderpest virus protects cattle against rinderpest and causes no pock lesions. Proc Natl Acad Sci U S A. 1991;88:8011–5. doi: 10.1073/pnas.88.18.8011. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Verardi PH, Aziz FH, Ahmad S, Jones LA, Beyene B, Ngotho RN, et al. Long-term sterilizing immunity to rinderpest in cattle vaccinated with a recombinant vaccinia virus expressing high levels of the fusion and hemagglutinin glycoproteins. J Virol. 2002;76:484–91. doi: 10.1128/JVI.76.2.484-491.2002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 42.Gudmundsdotter L, Nilsson C, Brave A, Hejdeman B, Earl P, Moss B, et al. Recombinant Modified Vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine. 2009;27:4468–74. doi: 10.1016/j.vaccine.2009.05.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. MOPH-TAVEG Investigators Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361:2209–20. doi: 10.1056/NEJMoa0908492. [DOI] [PubMed] [Google Scholar]
- 44.Sheehy SH, Duncan CJ, Elias SC, Biswas S, Collins KA, O’Hara GA, et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS One. 2012;7:e31208. doi: 10.1371/journal.pone.0031208. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Sheehy SH, Duncan CJ, Elias SC, Collins KA, Ewer KJ, Spencer AJ, et al. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther. 2011;19:2269–76. doi: 10.1038/mt.2011.176. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.O’Hara GA, Duncan CJ, Ewer KJ, Collins KA, Elias SC, Halstead FD, et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis. 2012;205:772–81. doi: 10.1093/infdis/jir850. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 47.Scriba TJ, Tameris M, Mansoor N, Smit E, van der Merwe L, Isaacs F, et al. Modified vaccinia Ankara-expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells. Eur J Immunol. 2010;40:279–90. doi: 10.1002/eji.200939754. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Youn JW, Hu YW, Tricoche N, Pfahler W, Shata MT, Dreux M, et al. Evidence for protection against chronic hepatitis C virus infection in chimpanzees by immunization with replicating recombinant vaccinia virus. J Virol. 2008;82:10896–905. doi: 10.1128/JVI.01179-08. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.de Waal L, Wyatt LS, Yüksel S, van Amerongen G, Moss B, Niesters HG, et al. Vaccination of infant macaques with a recombinant modified vaccinia virus Ankara expressing the respiratory syncytial virus F and G genes does not predispose for immunopathology. Vaccine. 2004;22:923–6. doi: 10.1016/j.vaccine.2003.10.010. [DOI] [PubMed] [Google Scholar]
- 50.Merkel TJ, Perera PY, Kelly VK, Verma A, Llewellyn ZN, Waldmann TA, et al. Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities. Proc Natl Acad Sci U S A. 2010;107:18091–6. doi: 10.1073/pnas.1013083107. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Guillaume V, Contamin H, Loth P, Georges-Courbot MC, Lefeuvre A, Marianneau P, et al. Nipah virus: vaccination and passive protection studies in a hamster model. J Virol. 2004;78:834–40. doi: 10.1128/JVI.78.2.834-840.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother. 2010;59:663–74. doi: 10.1007/s00262-009-0782-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28:1099–105. doi: 10.1200/JCO.2009.25.0597. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.National Library of Medicine (US). ClinicalTrials.gov [Internet]. Bethesda (MD), 2000- (accessed 2012 June 1).
- 55.Rountree RB, Mandl SJ, Nachtwey JM, Dalpozzo K, Do L, Lombardo JR, et al. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy. Cancer Res. 2011;71:5235–44. doi: 10.1158/0008-5472.CAN-10-4076. [DOI] [PubMed] [Google Scholar]
- 56.Mandl SJ, Rountree RB, Dalpozzo K, Do L, Lombardo JR, Schoonmaker PL, et al. Immunotherapy with MVA-BN®-HER2 induces HER-2-specific Th1 immunity and alters the intratumoral balance of effector and regulatory T cells. Cancer Immunol Immunother. 2012;61:19–29. doi: 10.1007/s00262-011-1077-4. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Harrop R, Drury N, Shingler W, Chikoti P, Redchenko I, Carroll MW, et al. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol Immunother. 2008;57:977–86. doi: 10.1007/s00262-007-0428-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Kaufman HL, Taback B, Sherman W, Kim DW, Shingler WH, Moroziewicz D, et al. Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J Transl Med. 2009;7:2. doi: 10.1186/1479-5876-7-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Amato RJ, Hawkins RE, Kaufman HL, Thompson JA, Tomczak P, Szczylik C, et al. Vaccination of metastatic renal cancer patients with MVA-5T4: a randomized, double-blind, placebo-controlled phase III study. Clin Cancer Res. 2010;16:5539–47. doi: 10.1158/1078-0432.CCR-10-2082. [DOI] [PubMed] [Google Scholar]
- 60.Harrop R, Shingler W, Kelleher M, de Belin J, Treasure P. Cross-trial analysis of immunologic and clinical data resulting from phase I and II trials of MVA-5T4 (TroVax) in colorectal, renal, and prostate cancer patients. J Immunother. 2010;33:999–1005. doi: 10.1097/CJI.0b013e3181f5dac7. [DOI] [PubMed] [Google Scholar]
- 61.Harrop R, Shingler WH, McDonald M, Treasure P, Amato RJ, Hawkins RE, et al. MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients. Cancer Immunol Immunother. 2011;60:829–37. doi: 10.1007/s00262-011-0993-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-Fauceglia P, Miller A, et al. Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A. 2012;109:5797–802. doi: 10.1073/pnas.1117208109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Dreicer R, Stadler WM, Ahmann FR, Whiteside T, Bizouarne N, Acres B, et al. MVA-MUC1-IL2 vaccine immunotherapy (TG4010) improves PSA doubling time in patients with prostate cancer with biochemical failure. Invest New Drugs. 2009;27:379–86. doi: 10.1007/s10637-008-9187-3. [DOI] [PubMed] [Google Scholar]
- 64.Quoix E, Ramlau R, Westeel V, Papai Z, Madroszyk A, Riviere A, et al. Therapeutic vaccination with TG4010 and first-line chemotherapy in advanced non-small-cell lung cancer: a controlled phase 2B trial. Lancet Oncol. 2011;12:1125–33. doi: 10.1016/S1470-2045(11)70259-5. [DOI] [PubMed] [Google Scholar]
- 65.Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, Jochems C, et al. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin Cancer Res. 2011;17:7164–73. doi: 10.1158/1078-0432.CCR-11-0649. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer. 2009;9:64–71. doi: 10.1038/nrc2545. [DOI] [PubMed] [Google Scholar]
- 67.McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK, et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res. 2001;61:8751–7. [PubMed] [Google Scholar]
- 68.Puhlmann M, Brown CK, Gnant M, Huang J, Libutti SK, Alexander HR, et al. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Ther. 2000;7:66–73. doi: 10.1038/sj.cgt.7700075. [DOI] [PubMed] [Google Scholar]
- 69.Liu TC, Hwang T, Park BH, Bell J, Kirn DH. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther. 2008;16:1637–42. doi: 10.1038/mt.2008.143. [DOI] [PubMed] [Google Scholar]
- 70.Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 2008;9:533–42. doi: 10.1016/S1470-2045(08)70107-4. [DOI] [PubMed] [Google Scholar]
- 71.Hwang TH, Moon A, Burke J, Ribas A, Stephenson J, Breitbach CJ, et al. A mechanistic proof-of-concept clinical trial with JX-594, a targeted multi-mechanistic oncolytic poxvirus, in patients with metastatic melanoma. Mol Ther. 2011;19:1913–22. doi: 10.1038/mt.2011.132. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 72.McCart JA, Mehta N, Scollard D, Reilly RM, Carrasquillo JA, Tang N, et al. Oncolytic vaccinia virus expressing the human somatostatin receptor SSTR2: molecular imaging after systemic delivery using 111In-pentetreotide. Mol Ther. 2004;10:553–61. doi: 10.1016/j.ymthe.2004.06.158. [DOI] [PubMed] [Google Scholar]
- 73.Chalikonda S, Kivlen MH, O’Malley ME, Eric Dong XD, McCart JA, Gorry MC, et al. Oncolytic virotherapy for ovarian carcinomatosis using a replication-selective vaccinia virus armed with a yeast cytosine deaminase gene. Cancer Gene Ther. 2008;15:115–25. doi: 10.1038/sj.cgt.7701110. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 74.Zhang Q, Yu YA, Wang E, Chen N, Danner RL, Munson PJ, et al. Eradication of solid human breast tumors in nude mice with an intravenously injected light-emitting oncolytic vaccinia virus. Cancer Res. 2007;67:10038–46. doi: 10.1158/0008-5472.CAN-07-0146. [DOI] [PubMed] [Google Scholar]
- 75.Gentschev I, Adelfinger M, Josupeit R, Rudolph S, Ehrig K, Donat U, et al. Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma. PLoS One. 2012;7:e37239. doi: 10.1371/journal.pone.0037239. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76.Yu YA, Galanis C, Woo Y, Chen N, Zhang Q, Fong Y, et al. Regression of human pancreatic tumor xenografts in mice after a single systemic injection of recombinant vaccinia virus GLV-1h68. Mol Cancer Ther. 2009;8:141–51. doi: 10.1158/1535-7163.MCT-08-0533. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 77.Yu YA, Timiryasova T, Zhang Q, Beltz R, Szalay AA. Optical imaging: bacteria, viruses, and mammalian cells encoding light-emitting proteins reveal the locations of primary tumors and metastases in animals. Anal Bioanal Chem. 2003;377:964–72. doi: 10.1007/s00216-003-2065-0. [DOI] [PubMed] [Google Scholar]
- 78.Plotke F, Lazowski ES. Comparative Results of Smallpox Revaccination Using Regular and Dry Smallpox Vaccine (Dryvax) IMJ Ill Med J. 1964;125:140–1. [PubMed] [Google Scholar]
- 79.Jones L, Giavedoni L, Saliki JT, Brown C, Mebus C, Yilma T. Protection of goats against peste des petits ruminants with a vaccinia virus double recombinant expressing the F and H genes of rinderpest virus. Vaccine. 1993;11:961–4. doi: 10.1016/0264-410X(93)90386-C. [DOI] [PubMed] [Google Scholar]
- 80.Mackett M, Yilma T, Rose JK, Moss B. Vaccinia virus recombinants: expression of VSV genes and protective immunization of mice and cattle. Science. 1985;227:433–5. doi: 10.1126/science.2981435. [DOI] [PubMed] [Google Scholar]
- 81.Meulemans G, Letellier C, Gonze M, Carlier MC, Burny A. Newcastle disease virus F glycoprotein expressed from a recombinant vaccinia virus vector protects chickens against live-virus challenge. Avian Pathol. 1988;17:821–7. doi: 10.1080/03079458808436504. [DOI] [PubMed] [Google Scholar]
- 82.Espion D, de Henau S, Letellier C, Wemers CD, Brasseur R, Young JF, et al. Expression at the cell surface of native fusion protein of the Newcastle disease virus (NDV) strain Italien from cloned cDNA. Arch Virol. 1987;95:79–95. doi: 10.1007/BF01311336. [DOI] [PubMed] [Google Scholar]
- 83.Carson C, Antoniou M, Ruiz-Argüello MB, Alcami A, Christodoulou V, Messaritakis I, et al. A prime/boost DNA/Modified vaccinia virus Ankara vaccine expressing recombinant Leishmania DNA encoding TRYP is safe and immunogenic in outbred dogs, the reservoir of zoonotic visceral leishmaniasis. Vaccine. 2009;27:1080–6. doi: 10.1016/j.vaccine.2008.11.094. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 84.Taylor J, Pincus S, Tartaglia J, Richardson C, Alkhatib G, Briedis D, et al. Vaccinia virus recombinants expressing either the measles virus fusion or hemagglutinin glycoprotein protect dogs against canine distemper virus challenge. J Virol. 1991;65:4263–74. doi: 10.1128/jvi.65.8.4263-4274.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 85.Cross ML, Fleming SB, Cowan PE, Scobie S, Whelan E, Prada D, et al. Vaccinia virus as a vaccine delivery system for marsupial wildlife. Vaccine. 2011;29:4537–43. doi: 10.1016/j.vaccine.2011.04.093. [DOI] [PubMed] [Google Scholar]
- 86.Papin JF, Verardi PH, Jones LA, Monge-Navarro F, Brault AC, Holbrook MR, et al. Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice. Proc Natl Acad Sci U S A. 2011;108:14926–31. doi: 10.1073/pnas.1112149108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87.Bakari M, Aboud S, Nilsson C, Francis J, Buma D, Moshiro C, et al. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine. 2011;29:8417–28. doi: 10.1016/j.vaccine.2011.08.001. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 88.Bart PA, Goodall R, Barber T, Harari A, Guimaraes-Walker A, Khonkarly M, et al. EuroVacc Consortium EV01: a phase I trial in healthy HIV negative volunteers to evaluate a clade C HIV vaccine, NYVAC-C undertaken by the EuroVacc Consortium. Vaccine. 2008;26:3153–61. doi: 10.1016/j.vaccine.2008.03.083. [DOI] [PubMed] [Google Scholar]
- 89.McCormack S, Stöhr W, Barber T, Bart PA, Harari A, Moog C, et al. EV02: a Phase I trial to compare the safety and immunogenicity of HIV DNA-C prime-NYVAC-C boost to NYVAC-C alone. Vaccine. 2008;26:3162–74. doi: 10.1016/j.vaccine.2008.02.072. [DOI] [PubMed] [Google Scholar]
- 90.Harari A, Bart PA, Stöhr W, Tapia G, Garcia M, Medjitna-Rais E, et al. An HIV-1 clade C DNA prime, NYVAC boost vaccine regimen induces reliable, polyfunctional, and long-lasting T cell responses. J Exp Med. 2008;205:63–77. doi: 10.1084/jem.20071331. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91.García F, Bernaldo de Quirós JC, Gómez CE, Perdiguero B, Nájera JL, Jiménez V, et al. Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02) Vaccine. 2011;29:8309–16. doi: 10.1016/j.vaccine.2011.08.098. [DOI] [PubMed] [Google Scholar]
- 92.Goepfert PA, Elizaga ML, Sato A, Qin L, Cardinali M, Hay CM, et al. National Institute of Allergy and Infectious Diseases HIV Vaccine Trials Network Phase 1 safety and immunogenicity testing of DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles. J Infect Dis. 2011;203:610–9. doi: 10.1093/infdis/jiq105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 93.Berthoud TK, Hamill M, Lillie PJ, Hwenda L, Collins KA, Ewer KJ, et al. Potent CD8+ T-cell immunogenicity in humans of a novel heterosubtypic influenza A vaccine, MVA-NP+M1. Clin Infect Dis. 2011;52:1–7. doi: 10.1093/cid/ciq015. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 94.Cavenaugh JS, Awi D, Mendy M, Hill AV, Whittle H, McConkey SJ. Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection. PLoS One. 2011;6:e14626. doi: 10.1371/journal.pone.0014626. [DOI] [PMC free article] [PubMed] [Google Scholar]